Hepatitis C | NASH
Hepatitis C | NASH
FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.
Hepatitis C - The Silent Epidemic
Hepatitis C (HCV), often labeled a “silent epidemic,” is a serious blood-borne disease, affecting almost 110 million people worldwide. The major modes of transmission include blood transfusion, surgical or invasive procedures, and intravenous (IV) drug use.
HCV is largely asymptomatic for many years; people often do not know they are infected until the disease is in an advanced state.
It is a silent killer that lurks under the radar.
Hepatitis C – 2014-2017 and Beyond"
This important collection of real-world insights is informed by scientifically validated, patient-reported, patient-experience data collected by Trio’s MDX platform.
If you are interested in downloading a copy of this book, please click here.
HCV Scientific Steering Committee
Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.
COMMITTEE MEMBER ACCOMPLISHMENTS
Publication
Journals
- Annals of Internal Medicine
- APS - American Physiological Society
- Clinical Gastroenterology
- Journal of Hepatology
- World Journal of Gastroenterology
- The New England Journal of Medicine
- Liver International
Associations
and Foundations
- AASLD Foundation
- American Board of Internal Medicine
- ACG
- ACP
- AGA
- American Liver Foundation
- Hepatitis B Foundation
- EASL
- NIH
Advisory Board
Affiliations
- AbbVie
- AEVI
- Angion
- Bristol-Myers Squibb
- Gilead
- Ligand
- Merck
- Salix
- Spring Bank
Publications & Abstracts
2019
"Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C” – Poster of Distinction Award
Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P. Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, Nezam H Afdhal
Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019
Conference dates: November 08, 2019 - November 12, 2019
Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management
Dr. Michael P. Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick and Nezam H Afdhal
Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019
Conference dates: November 08, 2019 - November 12, 2019
Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies
R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, D. Jayaweera
Poster Presented at: EACS – 17th European AIDS Conference
Conference dates: November 06, 2019 - November 09, 2019
Access to HCV Cure Under Medicaid Programs in the United States
Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai and Nezam Afdhal
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the Trio Network
Michael Curry, Bruce Bacon, Steven L Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US
Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer and Rick Elion
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network
Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging
Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging
Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: April 10, 2019 - April 14, 2019
2018
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network
Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 09, 2018 - November 13, 2018
Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOF-VEL): Data from the TRIO Network
Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 09, 2018 - November 13, 2018
Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network
Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 09, 2018 - November 13, 2018
Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network
Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 09, 2018 - November 13, 2018
Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network
Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai and Nezam Afdhal
Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 09, 2018 - November 13, 2018
Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network
Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: Global Hepatitis Summit (GHS)
Conference dates: June 14, 2018 - June 17, 2018
Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi and Nezam Afhdal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network
Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles and Karam Mounzer
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network
Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer and Rick Elion
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network
Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network
Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 02, 2018 - June 05, 2018
.jpeg)
Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network
Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer and Rick Elion
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network
Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer and Rick Elion
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network
Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
2017
Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network
M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi and N. Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network
Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network
Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network
C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi and N. Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)
C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi and N. Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network
Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network
Flamm SL, Bacon BR, Curry MP, Dieterich DT, Kowdley KV, Milligan S, Tsai NC, Younossi ZM and Afdhal NH
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 06, 2017 - May 09, 2017
Sofosbuvir/Velpatasvir in Genotype 2-6 HCV: Real-World Experience from the TRIO Network
Curry MP, Bacon BR, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Tsai NC, Younossi ZM and Afdhal NH
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: May 06, 2017 - May 09, 2017
Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network
Tsai NC, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Younossi ZM and Afdhal NH
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 06, 2017 - May 09, 2017
Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network
Younossi ZM, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Tsai NC and Afdhal NH
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 06, 2017 - May 09, 2017
Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network
Tsai NC, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Younossi ZM and Afdhal NH
Oral Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network
Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Nwankwo C, Tsai NC, Younossi ZM and Afdhal NH
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network
Younossi ZM, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Nwankwo C, Tsai NC, and Afdhal NH
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network
Flamm SL, Bacon B, Curry MP, Dieterich DT, Kowdley KV, Milligan S, Tsai NC, Younossi ZM and Afdhal NH
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Utilization of Sofosbuvir/Velpatasvir in Genotype 2-6 HCV: Real-World Experience from the TRIO Network
Tsai NC, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Younossi ZM and Afdhal NH
Oral Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
2016
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network
Korenblat K, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdle KV, Lee Y, Tsai NH, Younossi ZM and Afdhal NH
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 11, 2016 - November 15, 2016
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness
Buggisch P, Petersen J, Mauss S, Kowdley KV, Curry MP, Ruane PJ, Ain D, Tsai NC, Lee Y, Natha M, Eggleton E, Kreter B, Brainard DM and Ingiliz P
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Access to Therapy in Era of DAA Regimens: Real-World Experience from the TRIO Network
Dieterich DT, Bacon BR, Curry MP, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM and Afdhal NH
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network
Afdhal NH, Bacon BR, Curry MP, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network
Dieterich DT, Bacon BR, Curry MP, Flamm SL, Guest LE, Kowdley KV, Lee Y, Younossi ZM, Tsai NC and Afdhal NH
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Effectiveness of 8 or 12 week LDV/SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Curry MP, Bacon BR, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 21, 2016 - May 25, 2016
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network
Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven Flamm, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 25, 2016
Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Curry MP, Bacon BR, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, and Younossi ZM
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 21, 2016 - May 25, 2016
Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network
Afdhal NH, Bacon BR, Curry MP, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network
Flamm SL, Bacon BR, Curry MP, Dieterich DT, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM and Afdhal NH
Poster Presented at: International Liver Transplantation Society (ILTS)
Conference dates: May 04, 2016 - May 07, 2016
Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network
Dieterich DT, Bacon BR, Curry MP, Flamm SL, Guest LE, Kowdley KV, Lee Y, Younossi ZM, Tsai NC and Afdhal NH
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network
Flamm SL, Bacon BR, Curry MP, Dieterich DT, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM and Afdhal NH
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients in the TRIO Network
Afdhal NH, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness
Buggisch P, Petersen J, Mauss S, Kowdley KV, Curry MP, Ruane PJ, Ain D, Tsai NC, Lee Y, Natha M, Eggleton E, Kreter B, Brainard DM and Ingiliz P
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness
Buggisch P, Petersen J, Mauss S, Kowdley KV, Curry MP, Ruane PJ, Ain D, Tsai NC, Lee Y, Natha M, Eggleton E, Kreter B, Brainard DM and Ingiliz P
Poster Presented at: Asian Pacific Association for the Study of the Liver (APASL)
Conference dates: March 14, 2016 - March 15, 2016
Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network
Afdhal NH, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM
Poster Presented at: Asian Pacific Association for the Study of the Liver (APASL)
Conference dates: February 20, 2016 - February 24, 2016
2015
Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Curry MP, Bacon BR, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 13, 2015 - November 17, 2015
